NCT03241303View on ClinicalTrials.gov

Delineation of the Role of Glucagon-like Peptide-1 Signalling in Relation to Increased Carbohydrate Content in the Distal Small Intestines

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 1, 2017

Primary Completion Date

January 1, 2018

Study Completion Date

January 1, 2018

Conditions

Glucose Metabolism Disorders

Interventions

DRUG

Acarbose

Glucobay tablets on experimental day.

DRUG

Placebo Oral Tablet

Placebo tablets on experimental day.

DRUG

Exendin (9-39)

Infusion of GLP-1 receptor antagonist as a study tool to block GLP-1 activity on experimental day.

DRUG

Placebo Saline

9 mg/ml placebo saline infusion on experimental day.

Trial Locations (1)

2900

Center for Diabetesresearch, Hellerup

All Listed Sponsors

collaborator

University of Copenhagen

OTHER

lead

University Hospital, Gentofte, Copenhagen

OTHER

NCT03241303 - Delineation of the Role of Glucagon-like Peptide-1 Signalling in Relation to Increased Carbohydrate Content in the Distal Small Intestines | Biotech Hunter | Biotech Hunter